Black Box Biotechnology B B B Black BoxBiotechnology
Retatrutide + Tirzepatide 60 mg (20 + 40) RESEARCH USE ONLY BLACK BOX BIOTECHNOLOGY · RET60

Retatrutide + Tirzepatide

Also known as: Triple + dual agonist blend
Metabolic & GLP-1 Blend In stock Box of 10 vials 2 references

High-mass co-formulation of retatrutide and tirzepatide for combination-agonist studies.

Black Box Biotechnology Retatrutide Black Box Biotechnology Tirzepatide

Available sizes

SKUPer vialPack
RET60 60 mg (20 + 40) 10 vials / box

Order Retatrutide + Tirzepatide

Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.

Quote on Telegram Quote on Signal

Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.

A 60 mg vial co-formulating 20 mg retatrutide 1 and 40 mg tirzepatide 2. Both are multi-receptor incretin agonists with published phase 2/3 evidence; the blend is supplied for laboratories comparing overlapping receptor-engagement profiles.

At a glance

  • 20 mg retatrutide + 40 mg tirzepatide per vial
  • Wholesale-scale mass per vial
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
Form
Lyophilized powder
Purity
HPLC-verified — Certificate of Analysis available on request
Pack size
Box of 10 vials
Storage
Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.

Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972 PubMed 37366315
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
    doi:10.1056/NEJMoa2206038 PubMed 35658024

Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.

Related

Often ordered together

More in Metabolic
Quote on Telegram